Hello Inside, a pioneering CGM-enabled metabolic health service designed specifically for women, has secured €1.65 million in seed finance headed by Verge Fund, a leading international HealthTech VC, and supported by major partners including DocMorris and Kapa Ventures. Current supporters include Lea-Sophie Cramer (Amorelie), Martin Murray (Waterdrop), Eric Demuth (Bitpanda), 10xFounders, Simon Capital, and Miele Ventures. Despite its $44 billion market size, FemTech garnered only 4% of health tech funding in 2023, making this investment vital for driving innovation and growth.
Scarlett Chen of Verge Fund emphasized Hello Inside's potential: "Their use of cutting-edge technology to address women's health needs is consistent with our mission." We envision a huge commercial opportunity and a beneficial worldwide influence on women's health."
Hello Inside uses continuous glucose monitoring (CGM) and AI to help women better understand their metabolic health. By tracking nutrition, activity, stress, and sleep, the platform enables users to make informed health decisions and interfaces with devices such as Oura Ring and Apple Health for a more comprehensive approach.
With great user engagement and an 80% weight-goal success rate in just 30 days, the company intends to test its concept and expand into B2B markets. CEO Mario Aichlseder emphasizes the platform's value. "Our technology goes beyond tracking to offer insights that drive meaningful health changes."
Hello Inside is primed for continued expansion, following in the footsteps of trailblazers such as Oura and Clue. FemTech has gained attention despite financial difficulties, due to recent successes and the rise of Flo, the first unicorn in EU health. By 2025, the business expects even greater growth and opportunity.
